Disorders of Lipid Metabolism and its Correction in Chronic Kidney Disease

O.O. Melnyk

Abstract


Chronic kidney disease — a proven risk factor of the development and progression of lipid metabolism disorders. The basis of these disorders — an increase in blood plasma cholesterol, triglycerides, low density lipoproteins and decreased levels of high density lipoproteins, apo AI and apo AII. There has been a decrease in the activity of enzymes: lipoprotein lipase, hepatic triglyceride lipase, lecithin-cholesterol acyltransferase. The use of lipid-modifying drugs — statins, fibrates, nicotinic acid was proposed.


Keywords


chronic kidney disease; cholesterol; triglycerides; low density lipoproteins; high density lipoproteins; apo AI; apo AII; lipoprotein lipase; hepatic triglyceride lipase; statins; fibrates; nicotinic acid

References


El Nahas A.M., Bello A.K. Chronic kidney disease: The global challenge // Lancet. — 2005. — № 365. — Р. 331-40.

Levey A.S., Atkins R., Coresh J. et al. Chronic kidney disease as a global public health problem: Approaches and initiatives — A position statement from Kidney Disease Improving Global Outcomes // Kidney Int. — 2007. — № 72. — Р. 247-59.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Proctice Guideline for the Evaluation and Management of Chronic Kidney Disease // Kidney Int. — 2013. — 3(Suppl.). — Р. 1-150.

Gröne E.F., Gröne H.J. Does hyperli pidemia injure the kidney? Nature clinical practice // Nephrology. — 2008. — № 4(8). — Р. 424-5.

Sarnak M.J., Levey A. Cardiovascular disease and chronic renal disease: a new paradigm // Am. J. Kidney Dis. — 2000. — № 35(4). — S117-131.

Keane W.F. Lipids and the kidney // Kidney international. — 1994. — № 46(3). — Р. 910-20.

Tareeva I.E., Kutyrina M.I., Nikolaev A.Yu. The braking of chronic renal failure // Therapeutic Archives. — 2000. — № 6. — Р. 9-14.

Virchow R., Chance F. Cellular pathology, as based on physiological and pathological histology // J. Churchill. — London, 1860. A more precise account of fatty metamorphosis. — Р. 351.

Jay V. Richard Bright: physician extraordinaire // Arch. Pathol. Lab. Med. — 2000. — № 124. — Р. 1262-1263.

Moorhead J.F., Chan M.K., El-Nahas M., Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease // Lancet. — 1982. — № 2. — Р. 1309-11.

Grone H.J., Walli A., Grone E., Niedmann P., Thiery J., Seidel D., Helmchen U. Induction of glomerulosclerosis by dietary lipids. A functional and morphologic study in the rat // Lab. Invest. — 1989. — № 60. — Р. 433-46.

Vaziri N.D., Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease // Blood Purif. — 2011. — № 31(1–3). — Р. 189-96.

Chen S.C., Hung C.C., Kuo M.C. et al. Association of dyslipidemia with renal outcomes in chronic kidney disease // PLoS One. — 2013. — № 8(2). — Е55643.

Urazlina C.E., Zhdanova T.V., Nazarov A.V. et al. Lipid metabolism in patients with chronic renal failure // Ural Medical Journal. — 2011. — № 2(80). — Р. 122-6.

Rovin B.H., Tan L.C. LDL stimulates mesangial fibronectin production and chemoattractant expression // Kidney international. — 1993. — № 43. — Р. 218-25.

Keane W.F., O’Donnell M.P., Kasiske B.L. Oxidative modification of low-density lipoproteins by mesangial cells // Journal of the American Society of Nephrology. — 1993. — № 4. — Р. 187-94.

Kume S., Uzu T., Araki S. et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet // Journal of the American Society of Nephrology. — 2007. — № 18. — Р. 2715-23.

Colina I.B. Hyperli pidemia in patients with chronic kidney disease: features and approaches to treatment // The attending physician. — 2012. — № 1. — Р. 63-70.

Colina I.B., Stavrovskaya U., Shilov E.M. Dysli pidemia, and chronic progressive renal disease // Ter. archive. — 2004. — № 76(9). — Р. 75-8.

Abrass C.K. Cellular lipid metabolism and the role of lipids in progressive renal disease // Am. J. Nephrol. — 2004. — № 24. — Р. 46-53.

Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences // Am. J. Physiol. Renal. Physiol. — 2006. — № 290. — F262-F272.

Bhowmik D., Tiwari S.C. Metabolic syndrome and chronic kidney disease // Indian J. Nephrol. — 2008. — № 18(1). — Р. 1-4.

Trevisan R., Dodesini A.R., Lepore G. Lipids and renal disease // J. Am. Soc. Nephrol. — 2006. — № 17. — S145-S147.

Kuznetsova E.B., Zhdanov T.V., Sadykova Yu.R. et al. Metabolic syndrome in nephrology patients // Ural Medical Journal. — 2011. — № 4. — Р. 34-41.

KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease // Kidney International. — 2013. — 3(Suppl.). — Р. 268-70.

National Kidney Foundation. KDOQI Clinical Practice Guidline for Diabetes and CKD: 2012 update // Am. J. Kidney Dis. — 2012. — № 60(5). — Р. 850-886.

Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guidline for Lipid Management in Chronic Kidney Disease // Kidney Int. — 2013. — 3(Suppl.). — Р. 259-305.




DOI: https://doi.org/10.22141/2307-1257.0.2.16.2016.72751

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru